Description
Clinical Trials in Heart Failure: Insights 2023-2024
Explore the latest advancements in heart failure management with this comprehensive overview of key clinical trials conducted between 2023-2024. This document includes critical analyses of groundbreaking studies, new therapeutic interventions, and emerging guidelines.
Key Highlights:
- Semaglutide for HFpEF: Significant improvements in symptoms, weight reduction, and physical limitations among patients with heart failure and obesity.
- Dapagliflozin in Acute Heart Failure: Improved quality of life and reduced biomarkers without compromising safety.
- Finererone for HFpEF: Reduced cardiovascular death and heart failure events in patients with mildly reduced ejection fraction.
- Innovative Therapies: Splanchnic nerve ablation and advanced cardiac resynchronization techniques explored for improved outcomes.
- Iron Supplementation Studies: Evaluations of ferric carboxymaltose in patients with reduced ejection fraction and iron deficiency.
- Emerging Medications: Sotagliflozin for post-discharge heart failure patients and novel applications for dapagliflozin in acute MI cases.
- Advanced Procedures: Catheter ablation in end-stage heart failure and transcatheter mitral-valve repair for mitral regurgitation.
Reviews
There are no reviews yet.